Oncology Venture appoints new Chief Financial Officer

Hoersholm, Denmark, February 5thh, 2018 – Oncology Venture Sweden AB (AktieTorget: OV) announces that the company reinforces its organization by the recruitment of Claus Frisenberg Pedersen to the position as Chief Financial Officer (“CFO”) and Chief Commercial Officer (“CCO”). Claus Frisenberg Pedersen will replace CFO Nikolaj Buhl Jensen, who will take a position as Senior Consultant in the management company Buhl Oncology (Buhl Krone Holding APS) – a major investor in Oncology Venture Sweden AB and Medical Prognosis Institute A/S.

Claus Frisenberg Pedersen (b. 1972) has a strong background in developing and executing corporate strategies from a broad array of companies and industries. Further, Frisenberg Pedersen has an extensive experience from developing financial and brand value for the companies he works with. Prior to joining Oncology Venture, Frisenberg Pedersen held the position as CEO of ECCO Shoes in Northern Europe for five years, where he was instrumental in developing ECCO’s global blueprint for retail Joint Ventures, and also played a key role in re-positioning the perception of the ECCO brand in Northern Europe. In his previous career Frisenberg Pedersen was partner in the strategy consulting firm Qvartz, and as such has advised many companies and private equity firms on topics like strategy, commercialization, brand development, retail expansion, sales management and general value creation.

“We are happy to welcome Claus Frisenberg Pedersen to Oncology Venture. His strategic and commercial competences, extensive international investor network and brand development expertise will strengthen the ability to build shareholder value based on our unique platform for developing cancer drugs with precision,” said Peter Buhl Jensen, CEO of Oncology Venture.

Nikolaj Buhl Jensen has been with Oncology Venture since 2014. He was instrumental for Oncology Venture’s funding by public funds and private investors during 2014/15 and secured institutional investment from Pre-Seed Innovation (Danish Venture Capital). Jensen was also pivotal for the listing of Oncology Venture’s shares on AktieTorget in 2015. Buhl Jensen will take a position as Senior Consultant in Buhl Oncology (Buhl Krone Holding APS), who is a major investor and management company for Oncology Venture APS and Medical Prognosis Institute A/S.

For further information, please contact 

 About Oncology Venture Sweden AB 

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP® – in order to significantly increase the probability of success in clinical trials. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 29 out of 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are first screened, and only the patients most likely to respond to the treatment will be treated. Via a more well-defined patient group, risks and costs are reduced while the development process becomes more efficient.   

The current product portfolio: LiPlaCis® for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for Prostate Cancer, and APO010: an immuno-oncology product for Multiple Myeloma. 

Oncology Venture has spun out two companies as Special Purpose Vehicles: 2X Oncology Inc. is a US based company focusing on precision medicine for women’s cancers, currently with a pipeline of three promising phase 2 product candidates. 

OV-SPV 2 is a Danish company that will test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor. 

This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on February 5th, 2018.